Politician says Russia vs Mexico football game will be interesting to watchSport June 23, 21:11
Kyrgyz president sees revival of relations with Russia as major result of his tenureWorld June 23, 20:49
Ex-premier says initiative to impeach Poroshenko stems from Ukraine’s economy collapseWorld June 23, 20:20
This week in photos: Confederations Cup opening and summer solstice celebrationsSociety & Culture June 23, 19:11
Turkish ambassador to Russia: Moscow and Ankara to join efforts in war on terrorWorld June 23, 18:45
Ukraine’s finance ministry files appeal to London Court against Russia in $3 bln debt caseBusiness & Economy June 23, 18:42
Ukrainian society tired of Poroshenko’s policy — expertRussian Politics & Diplomacy June 23, 17:58
Deutsche Welle sees Russian international broadcasters as threat to European ideasWorld June 23, 17:34
Watchdog claims Telegram provides means of communication to terroristsBusiness & Economy June 23, 16:45
UNITED NATIONS, November 14. /TASS/. If the tests of experimental vaccines against the Ebola virus are successful, they will be available next year, UN Secretary-General’s special envoy David Nabarro said on Thursday. According to him, there are two highly promising potential vaccines. Sierra Leone’s Permanent Representative to the United Nations Vandi Chidi Minah told reporters that he expected “good news” about the results of the tests by the end of the current year.
According to the World Health Organization (WHO), the number of fatalities of the fever epidemic outbreak in West Africa has exceeded 5,100 people and 14,100 people have been infected. The situation is the most serious in Guinea, Liberia and Sierra Leone.
A number of countries are actively developing the Ebola vaccine. The UK, Japan, Russia and China have made progress in this area. On Wednesday, the international humanitarian organization Doctors Without Borders announced it would hold in December the vaccine testing in three medical centres in West Africa. Russia and China this week has allocated tens of millions of dollars for the development of the antiviral drugs.